Send to

Choose Destination
Lancet. 2009 Feb 7;373(9662):473-81. doi: 10.1016/S0140-6736(08)61246-5. Epub 2008 Sep 24.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Collaborators (133)

Alvarado-Ruiz R, Arechavaleta-Granell M, Cartas M, García-Hernández P, Gonzalez-Galvez G, Gonzalez-Villalpando C, Mar-Arevalo F, Morales-Flores H, Olvera-Alvarez I, Rios-Rodriguez E, Rodriguez-Pattzi H, Salinas-Gonzalez F, Sauque-Reyna L, Sosa-Camas R, Tamez-Perez H, Violante-Ortiz R, Abbott L, Arakaki R, Austin J, Bailey T, Bertolino J, Bettis R, Blonde L, Bode B, Bressler P, Brusco O, Cefalu W, Chisolm O, Rothman J, Corbett B, Crockett S, Cullen E, Downey H, Duckor S, Farmer H, Farrell J, Feinglos M, Fusco F, Garber A, Gilbert J, Goldstein B, Gollapudi G, Graf R, Greco S, Hartman I, Hassman D, Mudaliar S, Hodge R, Hoffman B, Hollander P, Jain R, Kaplan R, Kapoor A, Kawley A, Klein E, Landgarten S, Carroll M, Leslie H, Licata A, Linden D, Lipetz R, Magee M, McGill J, Clarke D, Mezitis N, Morris L, Mulmed L, O'Barr T, Olansky L, Ollins R, Palte S, Pearlstein R, Peterson G, Phillips L, Popeil L, Powers C, Race J, Reeves M, Reynolds L, Rivera-Colon L, Rosenstock J, Sharma S, Schumacher D, Schwartz S, Seidman B, Shelmet J, Shepherd M, Silver B, Smith T, Snell P, Snyder B, Sugimoto D, Sussman A, Tamayo R, Tisovec R, Trevino M, Cheatham W, Wahl T, Warren M, Weinrib S, Weinstein R, Weinstock R, Weiss D, Williams R, Winer N, Witkin D, Wittmer B, Cox M, Zisser H, East H, Barrera J, Gilman R, Robinson M, Pullman J, Anjani D, Reichman A, Thigpen D, Zieve F, Fishman N, Mather K, Abelseth J, Camacho P, DeHaven J, Molitch M, Corder C, Griffing G, Huffman D, Hunt G, Lochner J, Ratcliff L, Shomali M, Leichter S, Umpierrez G.

Author information

Baylor College of Medicine, Houston, TX, USA.



New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to investigate the safety and efficacy of liraglutide as monotherapy for this disorder.


In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks. The primary outcome was change in proportion of glycosylated haemoglobin (HbA(1c)). Analysis was done by intention-to-treat. This trial is registered with, number NTC00294723.


At 52 weeks, HbA(1c) decreased by 0.51% (SD 1.20%) with glimepiride, compared with 0.84% (1.23%) with liraglutide 1.2 mg (difference -0.33%; 95% CI -0.53 to -0.13, p=0.0014) and 1.14% (1.24%) with liraglutide 1.8 mg (-0.62; -0.83 to -0.42, p<0.0001). Five patients in the liraglutide 1.2 mg, and one in 1.8 mg groups discontinued treatment because of vomiting, whereas none in the glimepiride group did so.


Liraglutide is safe and effective as initial pharmacological therapy for type 2 diabetes mellitus and leads to greater reductions in HbA(1c), weight, hypoglycaemia, and blood pressure than does glimepiride.


[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center